Skip to main content
. 2023 Jan 13;15(2):507. doi: 10.3390/cancers15020507

Figure 4.

Figure 4

Efficacy in patients with and without dose reductions because of AEs in the overall population of ibrutinib-treated patients. (a) Kaplan-Meier curve of investigator-assessed PFS; (b) Kaplan-Meier curve of OS. Abbreviations: AE, adverse event; OS, overall survival; PFS, progression-free survival.